<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.1 20151215//EN" "JATS-journalpublishing1-mathml3.dtd">
<article dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <front>
        <journal-meta>
            <journal-id></journal-id>
            <issn></issn>
        </journal-meta>
        <article-meta>
            <title-group>
                <article-title></article-title>
            </title-group>
            <pub-date>
                <year></year>
            </pub-date>
        </article-meta> 
    </front>
<back>
    <ref-list>
            <ref id="b1">
                <label>1. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Fournier</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Martin</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Zitvogel</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Kroemer</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Galluzzi</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Apetoh</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Trial Watch: adoptively transferred cells for anticancer immunotherapy</article-title>. 
                    <source>OncoImmunology</source>. 
                    <year>2017</year>
                    <month>Aug</month>;
                    <volume>6</volume>(
                    <issue>11</issue>):
                    <fpage>e1363139</fpage>. 
                    <pub-id pub-id-type="doi">10.1080/2162402X.2017.1363139</pub-id>
                    <pub-id pub-id-type="pmid">29147628</pub-id>
                    <issn>2162-4011</issn>
                </mixed-citation>
            </ref>
            <ref id="b2">
                <label>2. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Iribarren</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Bloy</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Buqué</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Cremer</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Eggermont</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Fridman</surname>
                            <given-names>WH</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Trial Watch: immunostimulation with Toll-like receptor agonists in cancer therapy</article-title>. 
                    <source>OncoImmunology</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>5</volume>(
                    <issue>3</issue>):
                    <fpage>e1088631</fpage>. 
                    <pub-id pub-id-type="doi">10.1080/2162402X.2015.1088631</pub-id>
                    <pub-id pub-id-type="pmid">27141345</pub-id>
                    <issn>2162-4011</issn>
                </mixed-citation>
            </ref>
            <ref id="b3">
                <label>3. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Mellman</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Coukos</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Dranoff</surname>
                            <given-names>G</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cancer immunotherapy comes of age</article-title>. 
                    <source>Nature</source>. 
                    <year>2011</year>
                    <month>Dec</month>;
                    <volume>480</volume>(
                    <issue>7378</issue>):
                    <fpage>480</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nature10673</pub-id>
                    <pub-id pub-id-type="pmid">22193102</pub-id>
                    <issn>0028-0836</issn>
                </mixed-citation>
            </ref>
            <ref id="b4">
                <label>4. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Vacchelli</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Bloy</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Aranda</surname>
                            <given-names>F</given-names>
                        </name>, 
                        <name>
                            <surname>Buqué</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Cremer</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Demaria</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Trial Watch: immunotherapy plus radiation therapy for oncological indications</article-title>. 
                    <source>OncoImmunology</source>. 
                    <year>2016</year>
                    <month>Jul</month>;
                    <volume>5</volume>(
                    <issue>9</issue>):
                    <fpage>e1214790</fpage>. 
                    <pub-id pub-id-type="doi">10.1080/2162402X.2016.1214790</pub-id>
                    <pub-id pub-id-type="pmid">27757313</pub-id>
                    <issn>2162-4011</issn>
                </mixed-citation>
            </ref>
            <ref id="b5">
                <label>5. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know</article-title>. 
                    <source>Nat Rev Clin Oncol</source>. 
                    <year>2011</year>
                    <month>Aug</month>;
                    <volume>8</volume>(
                    <issue>10</issue>):
                    <fpage>577</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nrclinonc.2011.116</pub-id>
                    <pub-id pub-id-type="pmid">21808266</pub-id>
                    <issn>1759-4774</issn>
                </mixed-citation>
            </ref>
            <ref id="b6">
                <label>6. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sliwkowski</surname>
                            <given-names>MX</given-names>
                        </name>, 
                        <name>
                            <surname>Mellman</surname>
                            <given-names>I</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Antibody therapeutics in cancer</article-title>. 
                    <source>Science</source>. 
                    <year>2013</year>
                    <month>Sep</month>;
                    <volume>341</volume>(
                    <issue>6151</issue>):
                    <fpage>1192</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.1241145</pub-id>
                    <pub-id pub-id-type="pmid">24031011</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b7">
                <label>7. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Dillman</surname>
                            <given-names>RO</given-names>
                        </name>, 
                        <name>
                            <surname>Cornforth</surname>
                            <given-names>AN</given-names>
                        </name>, 
                        <name>
                            <surname>McClay</surname>
                            <given-names>EF</given-names>
                        </name>, 
                        <name>
                            <surname>Depriest</surname>
                            <given-names>C</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma</article-title>. 
                    <source>Melanoma Manag</source>. 
                    <year>2019</year>
                    <month>May</month>;
                    <volume>6</volume>(
                    <issue>2</issue>):
                    <fpage>MMT20</fpage>. 
                    <pub-id pub-id-type="doi">10.2217/mmt-2018-0010</pub-id>
                    <pub-id pub-id-type="pmid">31406564</pub-id>
                    <issn>2045-0885</issn>
                </mixed-citation>
            </ref>
            <ref id="b8">
                <label>8. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Pol</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Bloy</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Buqué</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Eggermont</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Cremer</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Sautès-Fridman</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Trial Watch: peptide-based anticancer vaccines</article-title>. 
                    <source>OncoImmunology</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>4</volume>(
                    <issue>4</issue>):
                    <fpage>e974411</fpage>. 
                    <pub-id pub-id-type="doi">10.4161/2162402X.2014.974411</pub-id>
                    <pub-id pub-id-type="pmid">26137405</pub-id>
                    <issn>2162-4011</issn>
                </mixed-citation>
            </ref>
            <ref id="b9">
                <label>9. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Schwartzentruber</surname>
                            <given-names>DJ</given-names>
                        </name>, 
                        <name>
                            <surname>Lawson</surname>
                            <given-names>DH</given-names>
                        </name>, 
                        <name>
                            <surname>Richards</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <name>
                            <surname>Conry</surname>
                            <given-names>RM</given-names>
                        </name>, 
                        <name>
                            <surname>Miller</surname>
                            <given-names>DM</given-names>
                        </name>, 
                        <name>
                            <surname>Treisman</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2011</year>
                    <month>Jun</month>;
                    <volume>364</volume>(
                    <issue>22</issue>):
                    <fpage>2119</fpage>–
                    <lpage>27</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1012863</pub-id>
                    <pub-id pub-id-type="pmid">21631324</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b10">
                <label>10. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Maude</surname>
                            <given-names>SL</given-names>
                        </name>, 
                        <name>
                            <surname>Frey</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Shaw</surname>
                            <given-names>PA</given-names>
                        </name>, 
                        <name>
                            <surname>Aplenc</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Barrett</surname>
                            <given-names>DM</given-names>
                        </name>, 
                        <name>
                            <surname>Bunin</surname>
                            <given-names>NJ</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Chimeric antigen receptor T cells for sustained remissions in leukemia</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>2014</year>
                    <month>Oct</month>;
                    <volume>371</volume>(
                    <issue>16</issue>):
                    <fpage>1507</fpage>–
                    <lpage>17</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJMoa1407222</pub-id>
                    <pub-id pub-id-type="pmid">25317870</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b11">
                <label>11. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Newick</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Moon</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Albelda</surname>
                            <given-names>SM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Chimeric antigen receptor T-cell therapy for solid tumors</article-title>. 
                    <source>Mol Ther Oncolytics</source>. 
                    <year>2016</year>
                    <month>Apr</month>;
                    <volume>3</volume>:
                    <fpage>16006</fpage>. 
                    <pub-id pub-id-type="doi">10.1038/mto.2016.6</pub-id>
                    <pub-id pub-id-type="pmid">27162934</pub-id>
                    <issn>2372-7705</issn>
                </mixed-citation>
            </ref>
            <ref id="b12">
                <label>12. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Restifo</surname>
                            <given-names>NP</given-names>
                        </name>, 
                        <name>
                            <surname>Dudley</surname>
                            <given-names>ME</given-names>
                        </name>, 
                        <name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Adoptive immunotherapy for cancer: harnessing the T cell response</article-title>. 
                    <source>Nat Rev Immunol</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>12</volume>(
                    <issue>4</issue>):
                    <fpage>269</fpage>–
                    <lpage>81</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nri3191</pub-id>
                    <pub-id pub-id-type="pmid">22437939</pub-id>
                    <issn>1474-1733</issn>
                </mixed-citation>
            </ref>
            <ref id="b13">
                <label>13. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kalos</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>June</surname>
                            <given-names>CH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology</article-title>. 
                    <source>Immunity</source>. 
                    <year>2013</year>
                    <month>Jul</month>;
                    <volume>39</volume>(
                    <issue>1</issue>):
                    <fpage>49</fpage>–
                    <lpage>60</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.002</pub-id>
                    <pub-id pub-id-type="pmid">23890063</pub-id>
                    <issn>1074-7613</issn>
                </mixed-citation>
            </ref>
            <ref id="b14">
                <label>14.         </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Perica</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Varela</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Oelke</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Schneck</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Adoptive T Cell Immunotherapy for Cancer</article-title>. 
                    <source>Rambam Maimonides Med J</source>.
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>6</volume>(
                    <issue>1</issue>):
                    <fpage>e0004</fpage>–
                    <lpage>e0004</lpage>. 
                    <pub-id pub-id-type="doi">10.5041/RMMJ.10179 </pub-id>
                    <pub-id pub-id-type="pmid"> 25717386</pub-id>
                    <issn>    2076-9172</issn>
                </mixed-citation>
            </ref>
            <ref id="b15">
                <label>15. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Pardoll</surname>
                            <given-names>D</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Does the immune system see tumors as foreign or self?</article-title>
                    <source>Annu Rev Immunol</source>. 
                    <year>2003</year>;
                    <volume>21</volume>(
                    <issue>1</issue>):
                    <fpage>807</fpage>–
                    <lpage>39</lpage>. 
                    <pub-id pub-id-type="doi">10.1146/annurev.immunol.21.120601.141135</pub-id>
                    <pub-id pub-id-type="pmid">12615893</pub-id>
                    <issn>0732-0582</issn>
                </mixed-citation>
            </ref>
            <ref id="b16">
                <label>16. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Magalhaes</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Carvalho-Queiroz</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Hartana</surname>
                            <given-names>CA</given-names>
                        </name>, 
                        <name>
                            <surname>Kaiser</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Lukic</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Mints</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Facing the future: challenges and opportunities in adoptive T cell therapy in cancer</article-title>. 
                    <source>Expert Opin Biol Ther</source>. 
                    <year>2019</year>
                    <month>Aug</month>;
                    <volume>19</volume>(
                    <issue>8</issue>):
                    <fpage>811</fpage>–
                    <lpage>27</lpage>. 
                    <pub-id pub-id-type="doi">10.1080/14712598.2019.1608179</pub-id>
                    <pub-id pub-id-type="pmid">30986360</pub-id>
                    <issn>1471-2598</issn>
                </mixed-citation>
            </ref>
            <ref id="b17">
                <label>17. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>June</surname>
                            <given-names>C</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Promises and challenges of engineered T cell therapies</article-title>. 
                    <source>Hum Gene Ther</source>. 
                    <year>2009</year>;
                    <volume>20</volume>(
                    <issue>11</issue>):
                    <fpage>1361</fpage>-
                    <lpage>1361</lpage>
                    <issn>1043-0342</issn>
                </mixed-citation>
            </ref>
            <ref id="b18">
                <label>18. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Coussens</surname>
                            <given-names>LM</given-names>
                        </name>, 
                        <name>
                            <surname>Zitvogel</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Palucka</surname>
                            <given-names>AK</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Neutralizing tumor-promoting chronic inflammation: a magic bullet?</article-title>
                    <source>Science</source>. 
                    <year>2013</year>
                    <month>Jan</month>;
                    <volume>339</volume>(
                    <issue>6117</issue>):
                    <fpage>286</fpage>–
                    <lpage>91</lpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.1232227</pub-id>
                    <pub-id pub-id-type="pmid">23329041</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b19">
                <label>19. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Engblom</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Pfirschke</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Zilionis</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Da Silva Martins</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Bos</surname>
                            <given-names>SA</given-names>
                        </name>, 
                        <name>
                            <surname>Courties</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF
                        <sup>high</sup> neutrophils
                    </article-title>. 
                    <source>Science</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>358</volume>(
                    <issue>6367</issue>):
                    <fpage>eaal5081</fpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.aal5081</pub-id>
                    <pub-id pub-id-type="pmid">29191879</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b20">
                <label>20. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Gentles</surname>
                            <given-names>AJ</given-names>
                        </name>, 
                        <name>
                            <surname>Newman</surname>
                            <given-names>AM</given-names>
                        </name>, 
                        <name>
                            <surname>Liu</surname>
                            <given-names>CL</given-names>
                        </name>, 
                        <name>
                            <surname>Bratman</surname>
                            <given-names>SV</given-names>
                        </name>, 
                        <name>
                            <surname>Feng</surname>
                            <given-names>W</given-names>
                        </name>, 
                        <name>
                            <surname>Kim</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title>. 
                    <source>Nat Med</source>. 
                    <year>2015</year>
                    <month>Aug</month>;
                    <volume>21</volume>(
                    <issue>8</issue>):
                    <fpage>938</fpage>–
                    <lpage>45</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nm.3909</pub-id>
                    <pub-id pub-id-type="pmid">26193342</pub-id>
                    <issn>1078-8956</issn>
                </mixed-citation>
            </ref>
            <ref id="b21">
                <label>21. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Hanahan</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Coussens</surname>
                            <given-names>LM</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Accessories to the crime: functions of cells recruited to the tumor microenvironment</article-title>. 
                    <source>Cancer Cell</source>. 
                    <year>2012</year>
                    <month>Mar</month>;
                    <volume>21</volume>(
                    <issue>3</issue>):
                    <fpage>309</fpage>–
                    <lpage>22</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ccr.2012.02.022</pub-id>
                    <pub-id pub-id-type="pmid">22439926</pub-id>
                    <issn>1535-6108</issn>
                </mixed-citation>
            </ref>
            <ref id="b22">
                <label>22. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Syn</surname>
                            <given-names>NL</given-names>
                        </name>, 
                        <name>
                            <surname>Teng</surname>
                            <given-names>MW</given-names>
                        </name>, 
                        <name>
                            <surname>Mok</surname>
                            <given-names>TS</given-names>
                        </name>, 
                        <name>
                            <surname>Soo</surname>
                            <given-names>RA</given-names>
                        </name>
                    </person-group>. 
                    <article-title>De-novo and acquired resistance to immune checkpoint targeting</article-title>. 
                    <source>Lancet Oncol</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>18</volume>(
                    <issue>12</issue>):
                    <fpage>e731</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30607-1</pub-id>
                    <pub-id pub-id-type="pmid">29208439</pub-id>
                    <issn>1470-2045</issn>
                </mixed-citation>
            </ref>
            <ref id="b23">
                <label>23. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Chandran</surname>
                            <given-names>SS</given-names>
                        </name>, 
                        <name>
                            <surname>Klebanoff</surname>
                            <given-names>CA</given-names>
                        </name>
                    </person-group>. 
                    <article-title>T cell receptor-based cancer immunotherapy: emerging efficacy and pathways of resistance</article-title>. 
                    <source>Immunol Rev</source>. 
                    <year>2019</year>
                    <month>Jul</month>;
                    <volume>290</volume>(
                    <issue>1</issue>):
                    <fpage>127</fpage>–
                    <lpage>47</lpage>. 
                    <pub-id pub-id-type="doi">10.1111/imr.12772</pub-id>
                    <pub-id pub-id-type="pmid">31355495</pub-id>
                    <issn>0105-2896</issn>
                </mixed-citation>
            </ref>
            <ref id="b24">
                <label>24. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </name>, 
                        <name>
                            <surname>Yannelli</surname>
                            <given-names>JR</given-names>
                        </name>, 
                        <name>
                            <surname>Yang</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Topalian</surname>
                            <given-names>SL</given-names>
                        </name>, 
                        <name>
                            <surname>Schwartzentruber</surname>
                            <given-names>DJ</given-names>
                        </name>, 
                        <name>
                            <surname>Weber</surname>
                            <given-names>JS</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2</article-title>. 
                    <source>J Natl Cancer Inst</source>. 
                    <year>1994</year>
                    <month>Aug</month>;
                    <volume>86</volume>(
                    <issue>15</issue>):
                    <fpage>1159</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1093/jnci/86.15.1159</pub-id>
                    <pub-id pub-id-type="pmid">8028037</pub-id>
                    <issn>0027-8874</issn>
                </mixed-citation>
            </ref>
            <ref id="b25">
                <label>25. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Geukes Foppen</surname>
                            <given-names>MH</given-names>
                        </name>, 
                        <name>
                            <surname>Donia</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Svane</surname>
                            <given-names>IM</given-names>
                        </name>, 
                        <name>
                            <surname>Haanen</surname>
                            <given-names>JB</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Tumor-infiltrating lymphocytes for the treatment of metastatic cancer</article-title>. 
                    <source>Mol Oncol</source>. 
                    <year>2015</year>
                    <month>Dec</month>;
                    <volume>9</volume>(
                    <issue>10</issue>):
                    <fpage>1918</fpage>–
                    <lpage>35</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.molonc.2015.10.018</pub-id>
                    <pub-id pub-id-type="pmid">26578452</pub-id>
                    <issn>1574-7891</issn>
                </mixed-citation>
            </ref>
            <ref id="b26">
                <label>26. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Nguyen</surname>
                            <given-names>LT</given-names>
                        </name>, 
                        <name>
                            <surname>Saibil</surname>
                            <given-names>SD</given-names>
                        </name>, 
                        <name>
                            <surname>Sotov</surname>
                            <given-names>V</given-names>
                        </name>, 
                        <name>
                            <surname>Le</surname>
                            <given-names>MX</given-names>
                        </name>, 
                        <name>
                            <surname>Khoja</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Ghazarian</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2</article-title>. 
                    <source>Cancer Immunol Immunother</source>. 
                    <year>2019</year>
                    <month>May</month>;
                    <volume>68</volume>(
                    <issue>5</issue>):
                    <fpage>773</fpage>–
                    <lpage>85</lpage>. 
                    <pub-id pub-id-type="doi">10.1007/s00262-019-02307-x</pub-id>
                    <pub-id pub-id-type="pmid">30747243</pub-id>
                    <issn>0340-7004</issn>
                </mixed-citation>
            </ref>
            <ref id="b27">
                <label>27. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </name>, 
                        <name>
                            <surname>Packard</surname>
                            <given-names>BS</given-names>
                        </name>, 
                        <name>
                            <surname>Aebersold</surname>
                            <given-names>PM</given-names>
                        </name>, 
                        <name>
                            <surname>Solomon</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Topalian</surname>
                            <given-names>SL</given-names>
                        </name>, 
                        <name>
                            <surname>Toy</surname>
                            <given-names>ST</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report</article-title>. 
                    <source>N Engl J Med</source>. 
                    <year>1988</year>
                    <month>Dec</month>;
                    <volume>319</volume>(
                    <issue>25</issue>):
                    <fpage>1676</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1056/NEJM198812223192527</pub-id>
                    <pub-id pub-id-type="pmid">3264384</pub-id>
                    <issn>0028-4793</issn>
                </mixed-citation>
            </ref>
            <ref id="b28">
                <label>28. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Janeway</surname>
                            <given-names>CA</given-names>
                            <suffix>Jr</suffix>
                        </name>
                    </person-group>. 
                    <article-title>How the immune system protects the host from infection</article-title>. 
                    <source>Microbes Infect</source>. 
                    <year>2001</year>
                    <month>Nov</month>;
                    <volume>3</volume>(
                    <issue>13</issue>):
                    <fpage>1167</fpage>–
                    <lpage>71</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/S1286-4579(01)01477-0</pub-id>
                    <pub-id pub-id-type="pmid">11709297</pub-id>
                    <issn>1286-4579</issn>
                </mixed-citation>
            </ref>
            <ref id="b29">
                <label>29. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sewell</surname>
                            <given-names>AK</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Why must T cells be cross-reactive?</article-title>
                    <source>Nat Rev Immunol</source>. 
                    <year>2012</year>
                    <month>Sep</month>;
                    <volume>12</volume>(
                    <issue>9</issue>):
                    <fpage>669</fpage>–
                    <lpage>77</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nri3279</pub-id>
                    <pub-id pub-id-type="pmid">22918468</pub-id>
                    <issn>1474-1733</issn>
                </mixed-citation>
            </ref>
            <ref id="b30">
                <label>30. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Fesnak</surname>
                            <given-names>AD</given-names>
                        </name>, 
                        <name>
                            <surname>June</surname>
                            <given-names>CH</given-names>
                        </name>, 
                        <name>
                            <surname>Levine</surname>
                            <given-names>BL</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Engineered T cells: the promise and challenges of cancer immunotherapy</article-title>. 
                    <source>Nat Rev Cancer</source>. 
                    <year>2016</year>
                    <month>Aug</month>;
                    <volume>16</volume>(
                    <issue>9</issue>):
                    <fpage>566</fpage>–
                    <lpage>81</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/nrc.2016.97</pub-id>
                    <pub-id pub-id-type="pmid">27550819</pub-id>
                    <issn>1474-175X</issn>
                </mixed-citation>
            </ref>
            <ref id="b31">
                <label>31. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Morgan</surname>
                            <given-names>RA</given-names>
                        </name>, 
                        <name>
                            <surname>Dudley</surname>
                            <given-names>ME</given-names>
                        </name>, 
                        <name>
                            <surname>Wunderlich</surname>
                            <given-names>JR</given-names>
                        </name>, 
                        <name>
                            <surname>Hughes</surname>
                            <given-names>MS</given-names>
                        </name>, 
                        <name>
                            <surname>Yang</surname>
                            <given-names>JC</given-names>
                        </name>, 
                        <name>
                            <surname>Sherry</surname>
                            <given-names>RM</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Cancer regression in patients after transfer of genetically engineered lymphocytes</article-title>. 
                    <source>Science</source>. 
                    <year>2006</year>
                    <month>Oct</month>;
                    <volume>314</volume>(
                    <issue>5796</issue>):
                    <fpage>126</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.1129003</pub-id>
                    <pub-id pub-id-type="pmid">16946036</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b32">
                <label>32. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Bialer</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Horovitz-Fried</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Ya’acobi</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Morgan</surname>
                            <given-names>RA</given-names>
                        </name>, 
                        <name>
                            <surname>Cohen</surname>
                            <given-names>CJ</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Selected murine residues endow human TCR with enhanced tumor recognition</article-title>. 
                    <source>J Immunol</source>. 
                    <year>2010</year>
                    <month>Jun</month>;
                    <volume>184</volume>(
                    <issue>11</issue>):
                    <fpage>6232</fpage>–
                    <lpage>41</lpage>. 
                    <pub-id pub-id-type="doi">10.4049/jimmunol.0902047</pub-id>
                    <pub-id pub-id-type="pmid">20427762</pub-id>
                    <issn>0022-1767</issn>
                </mixed-citation>
            </ref>
            <ref id="b33">
                <label>33. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sommermeyer</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Uckert</surname>
                            <given-names>W</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells</article-title>. 
                    <source>J Immunol</source>. 
                    <year>2010</year>
                    <month>Jun</month>;
                    <volume>184</volume>(
                    <issue>11</issue>):
                    <fpage>6223</fpage>–
                    <lpage>31</lpage>. 
                    <pub-id pub-id-type="doi">10.4049/jimmunol.0902055</pub-id>
                    <pub-id pub-id-type="pmid">20483785</pub-id>
                    <issn>0022-1767</issn>
                </mixed-citation>
            </ref>
            <ref id="b34">
                <label>34. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Cohen</surname>
                            <given-names>CJ</given-names>
                        </name>, 
                        <name>
                            <surname>Li</surname>
                            <given-names>YF</given-names>
                        </name>, 
                        <name>
                            <surname>El-Gamil</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Robbins</surname>
                            <given-names>PF</given-names>
                        </name>, 
                        <name>
                            <surname>Rosenberg</surname>
                            <given-names>SA</given-names>
                        </name>, 
                        <name>
                            <surname>Morgan</surname>
                            <given-names>RA</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond</article-title>. 
                    <source>Cancer Res</source>. 
                    <year>2007</year>
                    <month>Apr</month>;
                    <volume>67</volume>(
                    <issue>8</issue>):
                    <fpage>3898</fpage>–
                    <lpage>903</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3986</pub-id>
                    <pub-id pub-id-type="pmid">17440104</pub-id>
                    <issn>0008-5472</issn>
                </mixed-citation>
            </ref>
            <ref id="b35">
                <label>35. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Voss</surname>
                            <given-names>RH</given-names>
                        </name>, 
                        <name>
                            <surname>Willemsen</surname>
                            <given-names>RA</given-names>
                        </name>, 
                        <name>
                            <surname>Kuball</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Grabowski</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Engel</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Intan</surname>
                            <given-names>RS</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells</article-title>. 
                    <source>J Immunol</source>. 
                    <year>2008</year>
                    <month>Jan</month>;
                    <volume>180</volume>(
                    <issue>1</issue>):
                    <fpage>391</fpage>–
                    <lpage>401</lpage>. 
                    <pub-id pub-id-type="doi">10.4049/jimmunol.180.1.391</pub-id>
                    <pub-id pub-id-type="pmid">18097040</pub-id>
                    <issn>0022-1767</issn>
                </mixed-citation>
            </ref>
            <ref id="b36">
                <label>36. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Stadtmauer</surname>
                            <given-names>EA</given-names>
                        </name>, 
                        <name>
                            <surname>Fraietta</surname>
                            <given-names>JA</given-names>
                        </name>, 
                        <name>
                            <surname>Davis</surname>
                            <given-names>MM</given-names>
                        </name>, 
                        <name>
                            <surname>Cohen</surname>
                            <given-names>AD</given-names>
                        </name>, 
                        <name>
                            <surname>Weber</surname>
                            <given-names>KL</given-names>
                        </name>, 
                        <name>
                            <surname>Lancaster</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>CRISPR-engineered T cells in patients with refractory cancer</article-title>. 
                    <source>Science</source>. 
                    <year>2020</year>
                    <month>Feb</month>;
                    <volume>367</volume>(
                    <issue>6481</issue>):
                    <fpage>eaba7365</fpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.aba7365</pub-id>
                    <pub-id pub-id-type="pmid">32029687</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b37">
                <label>37. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Tawara</surname>
                            <given-names>I</given-names>
                        </name>, 
                        <name>
                            <surname>Kageyama</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Miyahara</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <name>
                            <surname>Fujiwara</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>Nishida</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <name>
                            <surname>Akatsuka</surname>
                            <given-names>Y</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS</article-title>. 
                    <source>Blood</source>. 
                    <year>2017</year>
                    <month>Nov</month>;
                    <volume>130</volume>(
                    <issue>18</issue>):
                    <fpage>1985</fpage>–
                    <lpage>94</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2017-06-791202</pub-id>
                    <pub-id pub-id-type="pmid">28860210</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="b38">
                <label>38. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Kochenderfer</surname>
                            <given-names>JN</given-names>
                        </name>, 
                        <name>
                            <surname>Wilson</surname>
                            <given-names>WH</given-names>
                        </name>, 
                        <name>
                            <surname>Janik</surname>
                            <given-names>JE</given-names>
                        </name>, 
                        <name>
                            <surname>Dudley</surname>
                            <given-names>ME</given-names>
                        </name>, 
                        <name>
                            <surname>Stetler-Stevenson</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Feldman</surname>
                            <given-names>SA</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19</article-title>. 
                    <source>Blood</source>. 
                    <year>2010</year>
                    <month>Nov</month>;
                    <volume>116</volume>(
                    <issue>20</issue>):
                    <fpage>4099</fpage>–
                    <lpage>102</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2010-04-281931</pub-id>
                    <pub-id pub-id-type="pmid">20668228</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="b39">
                <label>39. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sadelain</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Brentjens</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Rivière</surname>
                            <given-names>I</given-names>
                        </name>
                    </person-group>. 
                    <article-title>The basic principles of chimeric antigen receptor design</article-title>. 
                    <source>Cancer Discov</source>. 
                    <year>2013</year>
                    <month>Apr</month>;
                    <volume>3</volume>(
                    <issue>4</issue>):
                    <fpage>388</fpage>–
                    <lpage>98</lpage>. 
                    <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0548</pub-id>
                    <pub-id pub-id-type="pmid">23550147</pub-id>
                    <issn>2159-8274</issn>
                </mixed-citation>
            </ref>
            <ref id="b40">
                <label>40. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Siegler</surname>
                            <given-names>EL</given-names>
                        </name>, 
                        <name>
                            <surname>Kim</surname>
                            <given-names>YJ</given-names>
                        </name>, 
                        <name>
                            <surname>Chen</surname>
                            <given-names>X</given-names>
                        </name>, 
                        <name>
                            <surname>Siriwon</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Mac</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Rohrs</surname>
                            <given-names>JA</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers</article-title>. 
                    <source>Mol Ther</source>. 
                    <year>2017</year>
                    <month>Dec</month>;
                    <volume>25</volume>(
                    <issue>12</issue>):
                    <fpage>2607</fpage>–
                    <lpage>19</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.ymthe.2017.08.010</pub-id>
                    <pub-id pub-id-type="pmid">28919377</pub-id>
                    <issn>1525-0016</issn>
                </mixed-citation>
            </ref>
            <ref id="b41">
                <label>41. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sadelain</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy</article-title>. 
                    <source>Annu Rev Cancer Biol</source>. 
                    <year>2017</year>;
                    <volume>1</volume>(
                    <issue>1</issue>):
                    <fpage>447</fpage>–
                    <lpage>66</lpage>. 
                    <pub-id pub-id-type="doi">10.1146/annurev-cancerbio-050216-034351</pub-id>
                    <issn>2472-3428</issn>
                </mixed-citation>
            </ref>
            <ref id="b42">
                <label>42. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Posey</surname>
                            <given-names>AD</given-names>
                            <suffix>Jr</suffix>
                        </name>, 
                        <name>
                            <surname>Clausen</surname>
                            <given-names>H</given-names>
                        </name>, 
                        <name>
                            <surname>June</surname>
                            <given-names>CH</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Distinguishing Truncated and Normal MUC1 Glycoform Targeting from Tn-MUC1-Specific CAR T Cells: Specificity Is the Key to Safety</article-title>. 
                    <source>Immunity</source>. 
                    <year>2016</year>
                    <month>Nov</month>;
                    <volume>45</volume>(
                    <issue>5</issue>):
                    <fpage>947</fpage>–
                    <lpage>8</lpage>. 
                    <pub-id pub-id-type="doi">10.1016/j.immuni.2016.10.015</pub-id>
                    <pub-id pub-id-type="pmid">27851918</pub-id>
                    <issn>1074-7613</issn>
                </mixed-citation>
            </ref>
            <ref id="b43">
                <label>43. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Rossig</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Bollard</surname>
                            <given-names>CM</given-names>
                        </name>, 
                        <name>
                            <surname>Nuchtern</surname>
                            <given-names>JG</given-names>
                        </name>, 
                        <name>
                            <surname>Rooney</surname>
                            <given-names>CM</given-names>
                        </name>, 
                        <name>
                            <surname>Brenner</surname>
                            <given-names>MK</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy</article-title>. 
                    <source>Blood</source>. 
                    <year>2002</year>
                    <month>Mar</month>;
                    <volume>99</volume>(
                    <issue>6</issue>):
                    <fpage>2009</fpage>–
                    <lpage>16</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood.V99.6.2009</pub-id>
                    <pub-id pub-id-type="pmid">11877273</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="b44">
                <label>44. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Mezzanzanica</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Canevari</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Mazzoni</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Figini</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Colnaghi</surname>
                            <given-names>MI</given-names>
                        </name>, 
                        <name>
                            <surname>Waks</surname>
                            <given-names>T</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells</article-title>. 
                    <source>Cancer Gene Ther</source>. 
                    <year>1998</year>
                    <month>Nov-Dec</month>;
                    <volume>5</volume>(
                    <issue>6</issue>):
                    <fpage>401</fpage>–
                    <lpage>7</lpage>.
                    <pub-id pub-id-type="pmid">9917095</pub-id>
                    <issn>0929-1903</issn>
                </mixed-citation>
            </ref>
            <ref id="b45">
                <label>45. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Sadelain</surname>
                            <given-names>M.</given-names>
                        </name>
                    </person-group>.
                    <article-title>CAR therapy: the CD19 paradigm</article-title>. 
                    <source>J Clin Invest</source>. 
                    <year>2015</year>
                    <month>Sep</month>;
                    <volume>125</volume>(
                    <issue>9</issue>):
                    <fpage>3392</fpage>–
                    <lpage>400</lpage>. 
                    <pub-id pub-id-type="doi">10.1172/JCI80010</pub-id>
                    <pub-id pub-id-type="pmid">26325036</pub-id>
                    <issn>0021-9738</issn>
                </mixed-citation>
            </ref>
            <ref id="b46">
                <label>46. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Karschnia</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Jordan</surname>
                            <given-names>JT</given-names>
                        </name>, 
                        <name>
                            <surname>Forst</surname>
                            <given-names>DA</given-names>
                        </name>, 
                        <name>
                            <surname>Arrillaga-Romany</surname>
                            <given-names>IC</given-names>
                        </name>, 
                        <name>
                            <surname>Batchelor</surname>
                            <given-names>TT</given-names>
                        </name>, 
                        <name>
                            <surname>Baehring</surname>
                            <given-names>JM</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells</article-title>. 
                    <source>Blood</source>. 
                    <year>2019</year>
                    <month>May</month>;
                    <volume>133</volume>(
                    <issue>20</issue>):
                    <fpage>2212</fpage>–
                    <lpage>21</lpage>. 
                    <pub-id pub-id-type="doi">10.1182/blood-2018-12-893396</pub-id>
                    <pub-id pub-id-type="pmid">30808634</pub-id>
                    <issn>0006-4971</issn>
                </mixed-citation>
            </ref>
            <ref id="b47">
                <label>47. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Porter</surname>
                            <given-names>DL</given-names>
                        </name>, 
                        <name>
                            <surname>Kalos</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Zheng</surname>
                            <given-names>Z</given-names>
                        </name>, 
                        <name>
                            <surname>Levine</surname>
                            <given-names>B</given-names>
                        </name>, 
                        <name>
                            <surname>June</surname>
                            <given-names>C</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Chimeric Antigen Receptor Therapy for B-cell Malignancies</article-title>. 
                    <source>J Cancer</source>. 
                    <year>2011</year>;
                    <volume>2</volume>:
                    <fpage>331</fpage>–
                    <lpage>2</lpage>. 
                    <pub-id pub-id-type="doi">10.7150/jca.2.331</pub-id>
                    <pub-id pub-id-type="pmid">21716851</pub-id>
                    <issn>0378-2360</issn>
                </mixed-citation>
            </ref>
            <ref id="b48">
                <label>48. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ghorashian</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Kramer</surname>
                            <given-names>AM</given-names>
                        </name>, 
                        <name>
                            <surname>Onuoha</surname>
                            <given-names>S</given-names>
                        </name>, 
                        <name>
                            <surname>Wright</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Bartram</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <name>
                            <surname>Richardson</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR</article-title>. 
                    <source>Nat Med</source>. 
                    <year>2019</year>
                    <month>Sep</month>;
                    <volume>25</volume>(
                    <issue>9</issue>):
                    <fpage>1408</fpage>–
                    <lpage>14</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/s41591-019-0549-5</pub-id>
                    <pub-id pub-id-type="pmid">31477906</pub-id>
                    <issn>1078-8956</issn>
                </mixed-citation>
            </ref>
            <ref id="b49">
                <label>49. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Brudno</surname>
                            <given-names>JN</given-names>
                        </name>, 
                        <name>
                            <surname>Lam</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Vanasse</surname>
                            <given-names>D</given-names>
                        </name>, 
                        <name>
                            <surname>Shen</surname>
                            <given-names>YW</given-names>
                        </name>, 
                        <name>
                            <surname>Rose</surname>
                            <given-names>JJ</given-names>
                        </name>, 
                        <name>
                            <surname>Rossi</surname>
                            <given-names>J</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma</article-title>. 
                    <source>Nat Med</source>. 
                    <year>2020</year>
                    <month>Feb</month>;
                    <volume>26</volume>(
                    <issue>2</issue>):
                    <fpage>270</fpage>–
                    <lpage>80</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/s41591-019-0737-3</pub-id>
                    <pub-id pub-id-type="pmid">31959992</pub-id>
                    <issn>1078-8956</issn>
                </mixed-citation>
            </ref>
            <ref id="b50">
                <label>50. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>D’Agostino</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Raje</surname>
                            <given-names>N</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?</article-title>
                    <source>Leukemia</source>. 
                    <year>2020</year>
                    <month>Jan</month>;
                    <volume>34</volume>(
                    <issue>1</issue>):
                    <fpage>21</fpage>–
                    <lpage>34</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/s41375-019-0669-4</pub-id>
                    <pub-id pub-id-type="pmid">31780814</pub-id>
                    <issn>0887-6924</issn>
                </mixed-citation>
            </ref>
            <ref id="b51">
                <label>51. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Shah</surname>
                            <given-names>N</given-names>
                        </name>, 
                        <name>
                            <surname>Chari</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Scott</surname>
                            <given-names>E</given-names>
                        </name>, 
                        <name>
                            <surname>Mezzi</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>Usmani</surname>
                            <given-names>SZ</given-names>
                        </name>
                    </person-group>. 
                    <article-title>B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches</article-title>. 
                    <source>Leukemia</source>. 
                    <year>2020</year>
                    <month>Apr</month>;
                    <volume>34</volume>(
                    <issue>4</issue>):
                    <fpage>985</fpage>–
                    <lpage>1005</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/s41375-020-0734-z</pub-id>
                    <pub-id pub-id-type="pmid">32055000</pub-id>
                    <issn>0887-6924</issn>
                </mixed-citation>
            </ref>
            <ref id="b52">
                <label>52. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Wrzesinski</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Paulos</surname>
                            <given-names>CM</given-names>
                        </name>, 
                        <name>
                            <surname>Kaiser</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Muranski</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Palmer</surname>
                            <given-names>DC</given-names>
                        </name>, 
                        <name>
                            <surname>Gattinoni</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells</article-title>. 
                    <source>J Immunother</source>. 
                    <year>2010</year>
                    <month>Jan</month>;
                    <volume>33</volume>(
                    <issue>1</issue>):
                    <fpage>1</fpage>–
                    <lpage>7</lpage>. 
                    <pub-id pub-id-type="doi">10.1097/CJI.0b013e3181b88ffc</pub-id>
                    <pub-id pub-id-type="pmid">19952961</pub-id>
                    <issn>1524-9557</issn>
                </mixed-citation>
            </ref>
            <ref id="b53">
                <label>53. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Ribas</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <name>
                            <surname>Wolchok</surname>
                            <given-names>JD</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cancer immunotherapy using checkpoint blockade</article-title>. 
                    <source>Science</source>. 
                    <year>2018</year>
                    <month>Mar</month>;
                    <volume>359</volume>(
                    <issue>6382</issue>):
                    <fpage>1350</fpage>–
                    <lpage>5</lpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id>
                    <pub-id pub-id-type="pmid">29567705</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
            <ref id="b54">
                <label>54. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Samstein</surname>
                            <given-names>RM</given-names>
                        </name>, 
                        <name>
                            <surname>Lee</surname>
                            <given-names>CH</given-names>
                        </name>, 
                        <name>
                            <surname>Shoushtari</surname>
                            <given-names>AN</given-names>
                        </name>, 
                        <name>
                            <surname>Hellmann</surname>
                            <given-names>MD</given-names>
                        </name>, 
                        <name>
                            <surname>Shen</surname>
                            <given-names>R</given-names>
                        </name>, 
                        <name>
                            <surname>Janjigian</surname>
                            <given-names>YY</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Tumor mutational load predicts survival after immunotherapy across multiple cancer types</article-title>. 
                    <source>Nat Genet</source>. 
                    <year>2019</year>
                    <month>Feb</month>;
                    <volume>51</volume>(
                    <issue>2</issue>):
                    <fpage>202</fpage>–
                    <lpage>6</lpage>. 
                    <pub-id pub-id-type="doi">10.1038/s41588-018-0312-8</pub-id>
                    <pub-id pub-id-type="pmid">30643254</pub-id>
                    <issn>1061-4036</issn>
                </mixed-citation>
            </ref>
            <ref id="b55">
                <label>55. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Siegel</surname>
                            <given-names>RL</given-names>
                        </name>, 
                        <name>
                            <surname>Miller</surname>
                            <given-names>KD</given-names>
                        </name>, 
                        <name>
                            <surname>Jemal</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Cancer statistics, 2019</article-title>. 
                    <source>CA Cancer J Clin</source>. 
                    <year>2019</year>
                    <month>Jan</month>;
                    <volume>69</volume>(
                    <issue>1</issue>):
                    <fpage>7</fpage>–
                    <lpage>34</lpage>. 
                    <pub-id pub-id-type="doi">10.3322/caac.21551</pub-id>
                    <pub-id pub-id-type="pmid">30620402</pub-id>
                    <issn>0007-9235</issn>
                </mixed-citation>
            </ref>
            <ref id="b56">
                <label>56. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Fagerberg</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Jonasson</surname>
                            <given-names>K</given-names>
                        </name>, 
                        <name>
                            <surname>von Heijne</surname>
                            <given-names>G</given-names>
                        </name>, 
                        <name>
                            <surname>Uhlén</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Berglund</surname>
                            <given-names>L</given-names>
                        </name>
                    </person-group>. 
                    <article-title>Prediction of the human membrane proteome</article-title>. 
                    <source>Proteomics</source>. 
                    <year>2010</year>
                    <month>Mar</month>;
                    <volume>10</volume>(
                    <issue>6</issue>):
                    <fpage>1141</fpage>–
                    <lpage>9</lpage>. 
                    <pub-id pub-id-type="doi">10.1002/pmic.200900258</pub-id>
                    <pub-id pub-id-type="pmid">20175080</pub-id>
                    <issn>1615-9853</issn>
                </mixed-citation>
            </ref>
            <ref id="b57">
                <label>57. </label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">
                        <name>
                            <surname>Uhlén</surname>
                            <given-names>M</given-names>
                        </name>, 
                        <name>
                            <surname>Fagerberg</surname>
                            <given-names>L</given-names>
                        </name>, 
                        <name>
                            <surname>Hallström</surname>
                            <given-names>BM</given-names>
                        </name>, 
                        <name>
                            <surname>Lindskog</surname>
                            <given-names>C</given-names>
                        </name>, 
                        <name>
                            <surname>Oksvold</surname>
                            <given-names>P</given-names>
                        </name>, 
                        <name>
                            <surname>Mardinoglu</surname>
                            <given-names>A</given-names>
                        </name>, 
                        <etal>et al</etal>
                    </person-group>.
                    <article-title>Proteomics. Tissue-based map of the human proteome</article-title>. 
                    <source>Science</source>. 
                    <year>2015</year>
                    <month>Jan</month>;
                    <volume>347</volume>(
                    <issue>6220</issue>):
                    <fpage>1260419</fpage>. 
                    <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
                    <pub-id pub-id-type="pmid">25613900</pub-id>
                    <issn>0036-8075</issn>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
</article>